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Background: VSN16R is an opener of neural, big-conductance, calcium-activated, potassium 
channels. We report the results of a phase 2a trial of twice daily oral tablet therapy in people with 
spasticity due to multiple sclerosis (MS).  
Methods: Subjects had confirmed diagnosis of MS, spasticity reported as 4 on the spasticity 
numerical rating scale (NRS) and modified Ashworth scale 2 in 2 or more lower limb muscle groups.  
Participants entered (i) a hospital-based, placebo-controlled, single ascending dose (SAD) group 
(100mg, 200mg, 400mg and 800mg) to assess pharmacokinetics (n=10), safety and drug tolerability 
(n=53) and (ii) a second group (Total n=156) to receive either a maximum-tolerated dose or up to 
400mg BID of VSN16R capsules or matching placebo. The primary end-point was reduction of 
spasticity as measured by the NRS, with secondary-outcomes including reduction of modified 
Ashworth and Tardieu Spasticity Scales, Penn spasm scale and 10m walk following treatment.  
Results: Pharmacokinetics and relative lack of adverse events in the SAD safety phase were 
consistent with phase I safety studies in healthy individuals and all people tolerated the single 
800mg dose. Therefore, all people were assigned to 400mg BID during the efficacy arm. Among the 
people who received VSN16R (n=77) the change in the NRS was -0.9 ± 1.50 in the VSN16R 400mg BID 
group and -1.1 ± 1.52 in the placebo group (n=79), giving a non-significant treatment difference of 
+0.20 (95% CI: -0.2 to +0.7, p=0.3434). There was no significant effect on the secondary endpoints. 
However, post-hoc analysis of people who responded (>30% inhibition of the NRS) to the 800mg 
dose in the SAD phase (n=10) demonstrated a significant (p< 0.02) inhibition in the NRS compared 
those receiving placebo during the multiple dosing arm. The drug was not associated with any 
sedation. Reported adverse effects were inconsistent and generally mild.  
Conclusions: VSN16R at the dose 400mg BID did not show activity in reducing spasticity in MS 
patients. The single dose of 800 mg showed activity in comparison to placebo in the dose escalation 
phase. VSN16R has a very good safety profile. Due to a short halflife of VSN16R further studies with 
higher doses and slow-release formulation may be warranted. (ClinicalTrials.gov number 
NCT02542787. EU trials register Number: 2014-004412-11).  
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